About Migraine


Migraine is under-recognized and undertreated1,2

More than 30 million adults suffer with migraine in the US2-4

In the American Migraine Prevalence and Prevention (AMPP) study, which surveyed households to identify people with migraine1:

~50% of people with migraine had received a migraine diagnosis image

Preventive treatment is underutilized in migraine2

According to the AMPP study2:

35% Migraine Candidates image
10% Migraine Preventive Users image

Migraine can have a profound impact on people’s lives2,5

Migraine can lead to reduced productivity and cost people valuable time for work, household tasks, and leisure2,5

Presentation Board Icon

Migraine may affect a person’s productivity at work2

  • Nearly 30% of people with migraine reported that their productivity at work was reduced by at least 50% in the previous 3 months in the AMPP study
House Icon

Migraine may affect a person’s productivity at home2,5

  • 85% of people reported substantial reductions in their ability to do household work or chores due to migraine in a survey of 389 people with migraine living with a household partner as reported in the family impact of migraine study
  • More than one-third of people with migraine reported that household productivity was reduced by at least 50% in the previous 3 months in the AMPP study
Calendar Icon

Migraine may cause a person to miss leisure time and activities5

  • 45% of people reported missing family, social, and leisure activities due to migraine in a survey of 389 people with migraine living with a household partner as reported in the family impact of migraine study
Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including anaphylaxis, angioedema, dyspnea, urticaria, and rash, have been reported with Emgality. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 04JUN2019